Prevalence of Steatosis and Steatohepatitis in Patients Undergoing Bariatric Surgery; a Biopsy-based Study

Inclusion Criteria: * Patients undergoing laparoscopic sleeve gastrectomy ≥18 years of age. * Able to give written informed consent. * Scheduled, independently from this study, to have a liver biopsy (LB). * Negative for hepatitis B surface antigen, anti-hepatitis C virus, hepatitis C virus-RNA, and hepatitis B virus DNA. * BMI greater than or equal to 40, or BMI greater than or equal to 35 with at least one obesity-related comorbid condition (including type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea (OSA), GERD, asthma, venous stasis disease, severe osteoarthritis, or considerably impaired quality of life). * Unsuccessful nonoperative weight loss attempts. * Mental health clearance. * Recent updates have included patients with a BMI of 30-35 with uncontrollable type 2 diabetes or metabolic syndrome as an indication for a laparoscopic sleeve gastrectomy. Exclusion Criteria: * Patients with ascites. * Pregnant women. * Patients with any active implantable medical device (such as pacemaker or defibrillator). * Patients who had undergone liver transplantation. * Patients with cardiac failure and significant valvular disease. * Patients with hemochromatosis. * Patients who refused to undergo liver biopsy or blood tests. * Patients with alcohol consumption above recommended limits (\>14 units/week for women and \>21 units/week for men; 1 unit = 8 g of ethanol). * Patients with a confirmed diagnosis of active malignancy or another terminal disease. * Patients participating in another clinical trial within the preceding 30 days